<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>E药经理人 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-24T23:13:45+08:00</updated>
  <subtitle>我们致力于成为医药行业意见领袖平台，我们记录和观察医药重大商业事件，展现这个行业的复杂和冲突，提供最前线的思想火花。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>史无前例！一年75家药企上市。科创板是否估值过高？创新泡沫2021会破裂吗？6000字长文解读2020年IPO节奏</title>
    <updated>2020-11-24T21:16:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-24:/s/HsLMjxiOoOkU6blBUlq1_g</id>
    <link href="https://mp.weixin.qq.com/s/HsLMjxiOoOkU6blBUlq1_g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【启思会】倒计时4天，请收好这份参会攻略</title>
    <updated>2020-11-24T21:16:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-24:/s/MKGfRb4eS68mONeNUCUc0A</id>
    <link href="https://mp.weixin.qq.com/s/MKGfRb4eS68mONeNUCUc0A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>赛诺菲迎来新一代“抗糖”王者，“产品+服务”颠覆慢病治疗</title>
    <updated>2020-11-24T21:16:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-24:/s/P-4UAXtuXJFDuJ73mAADqw</id>
    <link href="https://mp.weixin.qq.com/s/P-4UAXtuXJFDuJ73mAADqw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>第二批耗材集采即将来临？国家医保局对人工关节、除颤器等开展数据采集与价格监测</title>
    <updated>2020-11-24T21:16:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-24:/s/KHwuiKOzcc0GEsmlgcL6hg</id>
    <link href="https://mp.weixin.qq.com/s/KHwuiKOzcc0GEsmlgcL6hg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新冠病毒之战再传捷报    阿斯利康牛津疫苗发布新进展</title>
    <updated>2020-11-24T21:16:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-24:/s/-J7NFw7DCZ-H0KV-STJ3Kg</id>
    <link href="https://mp.weixin.qq.com/s/-J7NFw7DCZ-H0KV-STJ3Kg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>投资人视角｜有条件批准政策执行，创新药审评加速与国际接轨</title>
    <updated>2020-11-24T21:16:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-24:/s/YVOyk-IdQupvh2TSpPX-FQ</id>
    <link href="https://mp.weixin.qq.com/s/YVOyk-IdQupvh2TSpPX-FQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>恒瑞、信达、君实、百济PD-1谁的销量高？谁能取胜药价谈判？谁的适应症多？谁进治疗指南多？PD-(L)1价格战已在途！</title>
    <updated>2020-11-23T21:23:04+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/9BuUaUSqSd2zwpnvpUnTPQ</id>
    <link href="https://mp.weixin.qq.com/s/9BuUaUSqSd2zwpnvpUnTPQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>33个MNC集采品种降价，AZ、默沙东、辉瑞等涉及品种最多！</title>
    <updated>2020-11-23T21:23:04+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/mwHCiJ_bZ_CSHGmZQ0qxsw</id>
    <link href="https://mp.weixin.qq.com/s/mwHCiJ_bZ_CSHGmZQ0qxsw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>“使命驱动 诺言必践” 诺和诺德中国发布首份公益白皮书</title>
    <updated>2020-11-23T21:23:04+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/GENfN8I1Kg1KDxTpUr7sjA</id>
    <link href="https://mp.weixin.qq.com/s/GENfN8I1Kg1KDxTpUr7sjA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>创新重构医疗产业：几家欢喜几家愁，一江春水向东流！</title>
    <updated>2020-11-22T17:47:38+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-22:/s/O1bDedyApjMAtQze7s7t5w</id>
    <link href="https://mp.weixin.qq.com/s/O1bDedyApjMAtQze7s7t5w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>烂公司说自己并购了一个干细胞、基因诊断就能涨的时代过去了！</title>
    <updated>2020-11-22T17:47:38+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-22:/s/sifKIdihU5c5fa6v8VTQGg</id>
    <link href="https://mp.weixin.qq.com/s/sifKIdihU5c5fa6v8VTQGg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>复宏汉霖：中国创新出海“领航者”</title>
    <updated>2020-11-22T17:47:38+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-22:/s/JVRIH7L3f3wOgHO9VEdokg</id>
    <link href="https://mp.weixin.qq.com/s/JVRIH7L3f3wOgHO9VEdokg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>集采之下：嘉林与信立泰，相似的故事，不同的结局......</title>
    <updated>2020-11-21T21:02:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-21:/s/WDm7Fzm0ZWsAKJOpg3XrcA</id>
    <link href="https://mp.weixin.qq.com/s/WDm7Fzm0ZWsAKJOpg3XrcA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>替尼“大爆炸”启示录：36个上市，仅8个国产，仍有企业未收回成本！</title>
    <updated>2020-11-21T21:02:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-21:/s/RBQO1MRnDf7P0VWhvRiohw</id>
    <link href="https://mp.weixin.qq.com/s/RBQO1MRnDf7P0VWhvRiohw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国家医保局：有这些行为将被限制或中止挂网、投标、配送！</title>
    <updated>2020-11-20T21:19:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/xaPRatPzmpOHDqgAkTbjpw</id>
    <link href="https://mp.weixin.qq.com/s/xaPRatPzmpOHDqgAkTbjpw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>参天公司：以中国本土需求为导向，持续贡献中国眼科事业</title>
    <updated>2020-11-20T21:19:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/QLRCgDR8rN05VCkh84dRew</id>
    <link href="https://mp.weixin.qq.com/s/QLRCgDR8rN05VCkh84dRew" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>带量采购对医疗健康企业组织与人才管理的影响——怡安翰威特专题研究结果</title>
    <updated>2020-11-20T21:19:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/TiRBbTeXLGvRYeBByzDc-g</id>
    <link href="https://mp.weixin.qq.com/s/TiRBbTeXLGvRYeBByzDc-g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>AZ错失80亿美元生物类似药入场券，与三星韩国合资公司将清算</title>
    <updated>2020-11-20T21:19:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/wQOVGhoMRC-4rmAR054mZQ</id>
    <link href="https://mp.weixin.qq.com/s/wQOVGhoMRC-4rmAR054mZQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>971、君实PD-1曾被争议的快速上市，CDE发文明确了标准</title>
    <updated>2020-11-20T21:19:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/C2WJI3NtRm0y2q3Owp7MKg</id>
    <link href="https://mp.weixin.qq.com/s/C2WJI3NtRm0y2q3Owp7MKg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020全球最具潜力药品TOP10！K药第一，O药落选，T药补位……这家药企占两席</title>
    <updated>2020-11-19T22:48:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-19:/s/U42zvC9rYdzDwkwJKueuCA</id>
    <link href="https://mp.weixin.qq.com/s/U42zvC9rYdzDwkwJKueuCA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>